In the published literature, we identified 24 MS patients who received IFNβ as DMT and then developed thrombotic microangiopathy with kidney injury (Table 1; Allinovi et al., 2017; Azkune Calle et al., 2016; Broughton et al., 2011; Etemadifar et al., 2018; Hansen et al., 2009; Hunt et al., 2014; Kimura et al., 2011; Larochelle et al., 2014; Mahe et al., 2013; Manani et al., 2017; Nerrant et al., 2013; Olea et al., 2012; Orvain et al., 2014; Rubin et al., 2014; Vosoughi & Marriott, 2014; Yam et al., 2019). Here, IFNB1 is linked to myeloid sarcoma.